Some experts say oral versions of popular weight-loss drugs such as Wegovy could offer people more flexibility and ...

Let's look at why this news could be a game-changer for Eli Lilly and its stock.

People with type 2 diabetes taking the highest dose of Eli Lilly’s experimental drug orfoglipron lowered their blood sugar and lost 16 pounds on average after 40 weeks.

The success of GLP-1 weight loss injectable drugs – Ozempic, the GLP-1 diabetes shot from Novo Nordisk, and Eli Lilly’s weight loss treatment Zepbound and diabetes drug Mounjaro – has set ...

GLP-1 medication use spiked, as well ... Half of the participants got a weekly shot of semaglutide, the drug in Ozempic and ...

Former Playboy star Kendra Wilkinson revealed that she started taking a weight-loss drug but threw the medication away after ...

Eli Lilly’s shares shot up 11% pre-market on Thursday after orforglipron became the first small-molecule GLP-1 drug to ace a ...

Drugmaker Eli Lilly (LLY 14.56%) hasn't been exempt from the recent market pullback, but its stock shot higher following the announcement that its newest GLP-1 drug had successfully completed the ...

Last quarter alone, its two leading GLP-1 drugs, Mounjaro and Zepbound, generated a combined $5.4 billion in revenue. Zepbound revenue soared from $175.8 million to $1.9 billion, while Mounjaro ...